Could a Vaccine-Based Cancer Cure Be Around the Corner?

Whether or not you're an avid follower of the health-care sector, there's always something intriguing and innovative going on.

Over the past couple of years we've witnessed one tissue engineering company develop a platform that may one day soon manufacture human organs, while also observing the determination of a handful of biopharmaceutical companies as they took on global killer hepatitis-C and practically eradicated the disease in trials. In other words, there's always something to be excited about as an investor, even if the overall market doesn't always agree.

Earlier this week, however, we had one of those potentially jaw-dropping moments that makes the biotech sector such an exciting place to follow and invest.


Source: EMD Group.

Making medical history
According to a study conducted by the Mayo Clinic, Stacy Erholtz, a sufferer of multiple myeloma (a cancer of the bone marrow) which had spread throughout her body, experienced a complete remission (i.e., no detectable levels of cancer found) after receiving a gargantuan dose of the measles vaccine which, under normal dosing circumstances, could have inoculated 10 million people.

As Dr. Stephen Russell, a molecular medicine professor who led the study for Mayo Clinic, was quoted as saying last week in an interview with the Star Tribune, "It's a landmark. We've known for a long time that we can give a virus intravenously and destroy metastatic cancer in mice. Nobody's shown that you can do that in people before." The Mayo Clinic's next step is to study this so-called "measles blitzkrieg" in a larger number of patients to determine if it'd be effective in other types of cancer, as well as establish what level of virus might be needed to break down the natural defense mechanism of cancer cells in order to overwhelm them.

...But keeping it in context
Of course, we have to take into consideration two other major aspects of the Mayo Clinic study. First, it was a two-person study, and the other individual whose metastatic cancer was found primarily in their muscles didn't experience a complete remission like Stacy Erholtz. This could mean that the measles vaccine super-dose isn't an effective option on all cancer types, or it could be based on a person's genetic makeup.

The other factor to consider here is that while the super-dose of the measles worked on Stacy Erholtz, there are a ton of unknowns still left for researchers to explore, such as cancers' defense mechanism threshold, and why the measles vaccine so selectively worked on Erholtz' cancer but not on the other patient. Researchers are realistically still a ways off from having the answers to these questions. 


Source: EMD Group.

This could be the start of something powerful
Regardless of whether it takes three months or five years for Mayo Clinic researchers to begin filling in the blanks to its study, the results this week really highlight why researchers and investors might want to take vaccination and immunotherapeutic cancer solutions seriously. Putting that into context once again, one positive result doesn't mean we've found an end-all cancer cure, but it does demonstrate that the science behind treating cancer with vaccinations, whether it be through injectable viruses or immunotherapeutic boosts, could prove quite effective.

A few names to watch over the coming years
Obviously, it's worth keeping a watchful eye on global pharmaceutical giant Merck (NYSE: MRK  ) which manufactures a measles, mumps, and rubella virus vaccine (MMR). It remains to be seen if the measles virus given in large doses can be effective in other cancer scenarios; however if it is Merck may need to be prepared to supply an abundance of its vaccine.

But, I really feel this news places the spotlight on what's going on within the cancer immunotherapy space, whereby biopharmaceutical companies are utilizing the body's own defense system to enhance its chance of fighting cancer. Like the measles super-dose, this might not be an end-all cure, but it does represent an intriguing new option for patients and physicians that could improve patient care and quality of life.

Upcoming studies from Galena Biopharma (NASDAQ: GALE  ) and Peregrine Pharmaceuticals (NASDAQ: PPHM  ) are two in particular I'd certainly suggest monitoring.

Breast cancer cell, Source: National Cancer Institute, Wikimedia Commons.

Galena Biopharma's prized experimental immunotherapy is NeuVax, an adjuvant therapy designed to help HER2-negative breast cancer patients (the most common form of breast cancer) remain disease-free. Breast cancer is the second-most diagnosed cancer in the U.S. each year, so developing effective therapies to derail a relapse is incredibly important. In its final phase 2 results, at the 60-month mark just 5.6% of the NeuVax intent-to-treat group had a cancer relapse compared to 25.9% of the placebo group. This 78.4% recurrence reduction difference has given investors and breast cancer patients significant hope that Galena's phase 3 results may prove successful. 

Peregrine Pharmaceuticals' bavituximab is another exciting therapy which in mid-stage trials more than doubled median overall survival as a second-line non-small cell lung cancer therapy (12.1 months compared to 5.6 months for the placebo). Bavituximab works by blocking an immunosuppressive molecule found on the outside of cancer cells which allows them to go undetected by the immune system. The thought here is if they can be spotted easier, then the patients' immune system has a better chance to fight the disease. Phase 3 trials of bavituximab initiated enrollment back in December.

Yet, similar to the unknowns surrounding the Mayo Clinic's "measles blitzkrieg" trial these two experimental drugs aren't without their own unique risks. Historically smaller cancer-focused biotech companies have fared very poorly in phase 3 trials or have failed to garner the approval of the Food and Drug Administration when filing for a new drug application. In addition, many immunotherapy vaccine developers (not just Galena and Peregrine) are fairly small in nature and have limited funds for research. Although Galena has Abstral approved as a breakthrough cancer pain therapy, both it and Peregrine are burning cash at the moment and could struggle to survive if NeuVax and bavituximab aren't eventually approved.

This is truly an exciting time
Still, the landscape of vaccine-based therapy is changing rapidly, piquing investor interest, but more importantly lending hope to cancer patients, and the friends and family of those patients, that more effective treatments may be on the way. The Mayo Clinic's landmark study may be a long way from having all the answers, but the simple point that we're finally starting to ask the right questions is a victory in and of itself.

Beating cancer has been a long-term goal of researchers, and few investors understand more about the long term than Warren Buffett. Find out what stock this legendary investor has recently been buying 
Imagine a company that rents a very specific and valuable piece of machinery for $41,000... per hour (that's almost as much as the average American makes in a year!). And Warren Buffett is so confident in this company's can't-live-without-it business model, he just loaded up on 8.8 million shares. An exclusive, brand-new Motley Fool report details this company that already has over 50% market share. Just click HERE to discover more about this industry-leading stock for free... and join Buffett in his quest for a veritable landslide of profits!


Read/Post Comments (12) | Recommend This Article (16)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On May 17, 2014, at 1:58 PM, DoctorLewis4 wrote:

    A vaccine based cancer treatment is around the corner. Investing in this trend however is where it gets tricky. Picking the winning companies in this space right now is like playing the lottery. It is just too early to tell who will not only get there first but get it right.

  • Report this Comment On May 18, 2014, at 4:27 PM, johngunn51 wrote:

    The 2 most promising immunotherapies for cancer in mid stage clinical trials are listeria fused tumor antigens from Advaxis (ADVX), Princeton, and heat shock protein fused tumor antigens from Heat Biologics( HTBX) in Raleigh Durham. Both platforms are effective in destroying a broad range of cancer cells, and are scalable and inexpensive vaccines in that they do not require ex- vivo individual genome based production. In addition, both platforms are checkpoint inhibitor neutral. Both of these companies are microcaps w strong intellectual property and management and are selling now at what I consider an irrational discount from their offering prices. Lots of leverage on the upside from here with both. Best of luck and God Bless. John Gunn

  • Report this Comment On May 18, 2014, at 5:06 PM, Bradknowsall wrote:

    "We can give a virus intravenously and destroy metastatic cancer" - Isn't that what the doctor tried to do in "I am Legend" with Will Smith?

  • Report this Comment On May 18, 2014, at 8:16 PM, sharron wrote:

    This is truly exciting. I am and RN of over 30 years and have seen so many people with cancer both professionally. I know the measles vaccine is a live virus. It comes as MMR, measles mumps and rubella. I am curious if this is just measles, if the measles has been separated from the others and also in another case this week someone was "cured" of cancer of the gallbladder with the polio virus. I give the polio virus in adults and it is a dead virus. Not sure if the polio vaccine is given to children is also a live virus. Let us hope and pray this is the beginning of something big.

  • Report this Comment On May 18, 2014, at 10:27 PM, PAA wrote:

    What we really need is a vaccine to prevent stupidity.

    Cancer or any illness is generally preventable through educating people on how to correctly care for their bodies. This means eating real food from safe sources and not processed foods from companies who couldn't care less about your health. It means getting enough fresh air, sunshine, and exercise. It means consciously staying hydrated.

    How is a vaccine going to protect anyone from ignorance??

  • Report this Comment On May 19, 2014, at 11:10 AM, trojan1990 wrote:

    John Gunn--Actually the most promising company in this space is Genelux. I can understand why you would not mention or know about them because they are a private company. They use the vaccine virus (Smallpox). Not only do they have the best vector they also own many of the patents these other companies will have to use to get to market. If you put their name in the Clinicaltrials.gov website operated by NIH you will see the trials that are now completed or in the last cohort of patients being treated. Not only does the virus eradicate cancer it is also used as a diagnostic. By changing the payload on the virus doctors and clinicians can enhance PET, CT, MRI and optical imagery.

  • Report this Comment On May 19, 2014, at 11:40 AM, Dimity wrote:

    Oh please PPA.......my mother took care of her body like nobody I've ever seen before and she died of metastatic lung cancer last year. It's genetic....your DNA, etc. that determines cancer risk. Diet and exercise, etc. can only go so far to prevent disease. If your DNA mutates, all the diet and exercise in the world won't prevent cancer. Otherwise, how would you explain a 2 year old being diagnosed with cancer?

  • Report this Comment On May 19, 2014, at 4:46 PM, shubhamgoel7703 wrote:

    will this treatment be effective for ameloblastic carcinoma type cancer ?

  • Report this Comment On May 19, 2014, at 9:20 PM, elijed23 wrote:

    That would be great, if it is real. I guess cancer is a mutation of the cells for the most part. If we could have a vaccine for cancer, the world would be so much better.

    Elisa Jed | http://www.willowoak.org

  • Report this Comment On May 20, 2014, at 12:33 PM, Lz wrote:

    As an investor in PPHM, I have read through a lot of the news releases on the Peregrine Pharmaceutical investor relations site. Bavituximab is a very promising drug on fighting many types of cancers and viruses as it allows the body to detect cells that have PS (phosphatidylserine) molecules on the outside of cells. This molecule is usually located inside the membrane of healthy cells, but flips and becomes exposed on the outside of tumor cells. They have images of mice with cancerous tumors that show the effectiveness of this treatment that look very impressive. They also have another candidate, Cortara for brain cancer, that is getting ready for phase III clinical trial ( they are currently seeking a partner). They have about 8 different trials now for Bavituximab (one trial is in phase 3), one for their imaging agent, and one for Cotora.

  • Report this Comment On May 21, 2014, at 1:49 PM, investingNideas wrote:
  • Report this Comment On June 02, 2014, at 12:55 PM, 5306 wrote:

    What is truly baffling is that you write an article about cancer vaccines and fail to mention Dendreon and the 1st cancer vaccine ever....Provenge.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2960091, ~/Articles/ArticleHandler.aspx, 10/20/2014 4:18:31 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement